Author:
Song Yarong,Zhang Xin,Liu Minmin,Zhai Xiangjun,Liu Jianxun,Li Yi,Li Lili,Xiao Yiwei,Duan Zhongping,Jiang Jing,Ding Feng,Zhu Liguo,Jiang Jie,Zou Huaibin,Zhuang Hui,Wang Jie,Li Jie
Abstract
Abstract
Background
The long-term protective effect of hepatitis B vaccine (HepB), the incidence of hepatitis B virus (HBV) vaccine breakthrough infections (VBIs), and whether a booster HepB is necessary remain to be clarified in children born to mothers with chronic HBV infection.
Methods
Based on a long-term follow-up prospective cohort of 1177 hepatitis B surface antigen (HBsAg)-positive mothers and their paired infants which was established from 2009 to 2011, total 454 children with immunoprophylaxis success as determined by postvaccination serologic testing (PVST) at 7 months old were included in this study. Among the 454 children, 246 never had a booster HepB, and 208 children received a booster HepB from 1 to 5 years of age. Multivariate logistic regression analysis was used to analyse the risk factors for HBV VBIs.
Results
The hepatitis B surface antibody (anti-HBs) levels declined sharply from 7 months to 2 years old, and the anti-HBs seronegative rate in the children increased significantly from 2 years old. A total of 31 (6.83%) of the 454 children experienced VBIs, of which 7 had overt and 7 had occult HBV infections. Notably, 14 (45.16%) of the 31 children with VBIs were diagnosed at 2 years old, and all of them had anti-HBs positivity (> 10 mIU/mL) at 1 year old. Maternal hepatitis B e antigen (HBeAg) positivity, higher HBV DNA and HBsAg levels, lower initial infant anti-HBs levels and not receiving a booster HepB were independent risk factors for VBIs. The incidence of VBIs was significantly lower in children with a booster HepB than in nonboosted children (0.50 vs. 11.90%, P < 0.001), and none of the boosted children developed overt or occult HBV infection. The anti-HBs levels of 76.67% for the children with VBIs in the nonboosted group indicated positivity before VBIs was detected.
Conclusions
After the primary full immunization with HepB, children born to mothers with chronic HBV infection, especially the children with maternal HBeAg positivity, high HBV DNA levels, high HBsAg levels and/or low initial infant anti-HBs levels, were at a high risk of VBIs, and a booster HepB for these children before 2 years old, instead of when their anti-HBs level is < 10 mIU/mL, could reduce the incidence of VBIs.
Funder
National Major Scientific and Technological Special Project during the Thirteenth Five-Year Plan Period
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Hepatitis B. World Health Organization Fact Sheets. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed 1 May 2020.
2. Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 Update). J Clin Transl Hepatol. 2017;5(4):297–318. https://doi.org/10.14218/JCTH.2016.00019.
3. Global Hepatitis Report, 2017. Geneva: World Health Organization. 2017. https://www.who.int/publications/i/item/9789241565455. Accessed 19 Apr 2017.
4. Piratvisuth T. Optimal management of HBV infection during pregnancy. Liver Int. 2013;33:188–94. https://doi.org/10.1111/liv.12060.
5. Zhu CL, Liu P, Chen T, Ni Z, Lu LL, Huang F, et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine. 2011;29(44):7835–41. https://doi.org/10.1016/j.vaccine.2011.07.098.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献